FEATURESPACE
16.8.2022 16:02:11 CEST | Business Wire | Press release
Featurespace and Vital4 have signed a global partnership to provide the financial services industry with AI driven Watchlist, PEPs, Sanctions and Adverse Media screening through Featurespace’s award winning ARIC Risk Hub. With this partnership, ARIC Risk Hub for AML is a one stop, end-to-end financial crime prevention solution for the customer.
Through a single API, ARIC Risk Hub for AML will leverage the watchlist data collected and curated by Vital4 to enhance the performance of Featurespace’s self learning models, ultimately improving accuracy and reducing false positives in flagged entities and transactions. Vital4’s automated AML/ KYC data tools analyze more than 6,000 global watchlists to help identify subjects involved in sanctions, terrorism, or corruption.
“Given the complementary technologies of Featurespace and Vital4, the industry now has access to behavioral analytics coupled with sentiment analysis to truly identify the financial criminals in real time.” Said Dave Excell, Featurespace Founder.
Vital4’s AI driven system examines 13 important criteria to provide the highest levels of name-matching, removing the ambiguity of legacy systems that rely on fuzzy name matching that can miss critical data points.
“As financial crime becomes increasingly complex to combat, crossing borders and moving in real-time, AML professionals need a complete risk hub to effectively monitor and report suspicious transactions and remain compliant.” Said Amy Barbieri, Co-Founder and President of Vital4. “The risk of non-compliance has huge reputational impact, making the business case clear for technologies that improve the accuracy for anti-financial crime efforts”.
Featurespace and Vital4 are two Atlanta based AI driven technology companies led by industry leading women. The two companies are unified around a shared commitment to enable banks and financial instutions with the best technology to fight financial crime and make the world a safer place to transact.
Primary industry benefits:
AI Driven Watchlist Screening :
- Machine learning to manage increasing volume and variety of transactions and entities to screen and monitor
- Monitoring over 6,300 Watchlists and Global Sanctions in 200+ countries and regions
- Propriety entity and name matching to provide more accurate search results and reduce false positives
- Proprietary 13-point name matching algorithm – better than traditional fuzzy name matching logic
- Natural Language Processing and Sentiment Analysis to truly identify Adverse Media articles AI-powered tagging of individuals or businesses in articles
- Watchlists updated real-time
- Risk-based call-out depending on business rule logic, analytics output
Customer Screening
- Screening at onboarding, change of details and ongoing trigger-based or scheduled monitoring
- Risk-based screening policies determine depth of search
- Watchlist flags available for analysts and immediate use within rules
Real-time Transaction Screening
- Real-time enabled sanctions screening of specified transaction types (i.e. cross-border, wires, ACH)
- Screening of counterparties
- Instant responses and action tags
- Reviewed in context of wider account activity a single, intuitive UI
Featurespace continues to partner with best in class technologies to provide holistic FRAML solutions for smart thinking financial institutions. Featurespace's partnership with Vital4 provides customers with a consolidated view and ability to manage financial crime risks across AML, fraud and sanctions within a single next generation risk management platform. Featurespace’s partnership with Callsign provides Enhanced Authentication and Device ID and security is provided by Accertify, and Ciphertrace provides crypto intelligence for transactional monitoring.
About Featurespace
Featurespace is the world leader in enterprise grade technology that prevents fraud and fights financial crime. With a mission to make the world a safer place to transact, Featurespace helps banks and financial institutions protect consumers, and reduce risk and operating costs by providing industry-leading machine learning, financial crime prevention solutions. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks and is the first to profile both genuine and fraudulent behavior to identify and catch criminal activity in real time. Both are patent pending technologies that are central to Featurespace’s award winning ARIC™ Risk Hub. Over 70 direct customers and 100,000 merchants and financial institutions have put their trust in Featurespace’s technology including HSBC, NatWest, TSYS, Worldpay, Marqeta, Contis, Danske Bank, Akbank, Edenred and Permanent TSB. Founded in 2008, and headquartered in Cambridge, UK Featurespace has a team of over 400, operating globally from seven locations.
About Vital4
Vital4 is an award-winning global technology company that provides critical data to organizations for regulatory compliance and to help mitigate third-party risk. Striving to make the world a safer place, Vital4 helps identify illicit actors in the fight against financial crime, terrorism, fraud, and corruption. Vital4 was founded with four fundamental concepts in mind: compliance, accuracy, global insight, and value. The powerful search platform, Vital4Search, was built with a “tech first” approach anchored by AI and Machine learning and is the world’s fastest and most accurate proprietary data search technology on the market today. Vital4Search solves enterprise compliance problems by eliminating slow update cycles, shallow source pools and reducing the human error risk of manual legacy processes. Vital4 provides data solutions to thousands of users in banking, gaming, identity, gig economy, GRC, legal, insurance and 4 of the top 5 largest background screening companies in the world put their trust in Vital4.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
